While many see Elias Zerhouni's attempt to make his support for new investigators permanent NIH policy a good thing, DrugMonkey doesn't think the issue of who-gets-what is so clear-cut. He says it's the inherent bias in peer review that needs to be changed, and that Band-Aid solutions like the so-called affirmative action favoring young or first-time grant applicants are masking the real problem. "How so?

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.